New injection could fight stubborn joint infections after knee surgery
NCT ID NCT06889701
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called TNP-2092, given as an injection into the knee joint, for people with infections after knee replacement surgery. The study includes 33 participants and compares the new drug to standard antibiotics. The main goal is to check safety and how the drug behaves in the body, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TNP-2092 (rifaquizinone) injection
What this could lead to
If it works, this could offer a new treatment option for stubborn joint infections after knee replacement, potentially reducing the need for long-term antibiotics.
What could go wrong
This is a very early phase 1/2 study with only 33 participants, so it is too soon to know if it works. The main focus is safety, and there may be side effects or no benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPROSTHETIC JOINT INFECTION (PJI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xinjiang Medical University
RECRUITINGÜrümqi, Xinjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••